Company news

Fennec Pharmaceuticals Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024

March 18, 2024

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand

March 16, 2024

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

February 28, 2024

FDA Issues Reminder of Non-Substitution of PEDMARK® (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin

January 31, 2024

Fennec Announces Incremental $5 Million Investment from Petrichor

December 4, 2023

Fennec Pharmaceuticals Announces Third Quarter 2023 Financial Results and Provides Business Update

November 5, 2023

Fennec Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 6, 2023

October 29, 2023

Fennec Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Business Update

August 2, 2023

Fennec Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 3, 2023

July 30, 2023

Fennec Pharmaceuticals Announces European Commission Marketing Authorization for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

June 5, 2023

Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023

Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

May 7, 2023

Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients

March 30, 2023

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2022 Financial Results

March 29, 2023

Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA

January 30, 2023

Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients

January 24, 2023

Fennec Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Business Update

November 10, 2022

Fennec Pharmaceuticals Announces Commercial Availability of PEDMARK® (sodium thiosulfate injection) in the United States

October 16, 2022

Fennec Pharmaceuticals Announces Second Closing of $20 Million Investment from Petrichor

September 25, 2022

Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection)

September 20, 2022

Fennec Pharmaceuticals Closes First $5 Million Investment From Petrichor

August 21, 2022

Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update

August 11, 2022

Fennec Pharmaceuticals Announces Up to $45 Million Investment From Petrichor

July 31, 2022

Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

May 11, 2022

Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™

April 26, 2022

Fennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth Conference

March 24, 2022

Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for Pedmark™

March 23, 2022

Fennec Pharmaceuticals Announces Fiscal Year 2021 Financial Results And Provides Business Update

February 27, 2022

Fennec Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors

November 29, 2021

Fennec Pharmaceuticals Expects to Receive Complete Response Letter from the FDA for its New Drug Application for PEDMARK™ to Prevent Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic, Solid Tumors

November 28, 2021

Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update

November 9, 2021

Fennec Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update

August 9, 2021

Fennec Pharmaceuticals Announces Amendment to Increase Existing Senior Debt Facility

June 23, 2021

Fennec Pharmaceuticals Announces FDA Acceptance of New Drug Application Resubmission for PEDMARK™

June 21, 2021

Fennec Pharmaceuticals Resubmits New Drug Application to U.S. Food and Drug Administration for PEDMARK™

May 27, 2021

Fennec Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update

May 12, 2021

Fennec Announces Fiscal Year 2020 Financial Results and Provides Business Update

March 29, 2021

Fennec Pharmaceuticals Announces Third Quarter 2020 Financial Results and Provides Business Update

November 15, 2020

Fennec Announces Issuance of U.S. Patent for PEDMARK™

September 20, 2020

Fennec Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Business Update

August 4, 2020

Fennec Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Business Update

May 13, 2020

Fennec Announces Exercise and Closing of Underwriters’ Option to Purchase Additional Shares

May 7, 2020

Fennec Announces Closing of Public Offering

May 4, 2020

Fennec Announces Pricing of Public Offering

April 29, 2020

Fennec Announces Proposed Public Offering of Common Shares

April 28, 2020

Fennec Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of New Drug Application for PEDMARK™

April 12, 2020

Fennec Announces Issuance of U.S. Patent for Use of PEDMARK™

March 4, 2020

Fennec Pharmaceuticals Receives European Medicines Agency Validation for Marketing Authorization Application for Sodium Thiosulfate

February 27, 2020

Fennec Provides Business Update and Announces Fiscal Year 2019 Financial Results

February 13, 2020

Fennec Pharmaceuticals Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for PEDMARK™ and Also Submits Marketing Authorization Application (MAA) to European Medicines Agency

February 10, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 14 calls. Every call is listed under its year.

Decks

The 5 newest of 42 decks. Every deck is listed under its year.